Mithra Demonstrates Further Estetrol’s Unique Profile at the Annual Meeting of the Endocrine Society

Liege, Belgium, 25 March 2019 – 7 :30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health has presented the results of a new study on Estetrol (E4) at the 101st Annual Meeting of the Endocrine Society (ENDO 2019) held from March 23 to 26 in New Orleans (U.S.)

 

Mithra Reports 2018 Annual Results

  • Strong revenue growth (+42%) with significantly improved EBITDA (record level of EUR 38.3 M vs. EUR -18.4 M in 2017) and cash position (EUR 119 M vs. EUR 36.2 M in 2017) thanks to increased business development activities
  • Strengthening Mithra’s international deployment through key partnerships with women’s health leaders
  • Clinical milestones successfully achieved for highly promising portfolio E4 (Estetrol)-based pipeline, including the 5th generation contraceptive pill Estelle® and next-generation menopause therapy Donesta®
  • Additional potential E4-based blockbuster for the underserved perimenopause market with PeriNesta™ in development (which brings Mithra’s late clinical stage pipeline to a total of 3)

Liege, Belgium, 01 March 2019– 7 :30 CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces its results for the year ended 31 December 2018, prepared in accordance with IFRS.

Information on the Total Number of Voting Rights (Denominator)

Liege, Belgium, 25 February 2019 – 17:45 CET – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Mithra Pharmaceuticals SA announces the following information, following the issuance of 24,750 new shares on 30 January 2019 for an amount of EUR 84 690 as the result of the exercise of 15 subscription rights (warrants) pursuant to the warrant plan initiated on 2 March 2015. Following this capital increase, Mithra now has 37.664.245 outstanding shares carrying voting rights (37,639,495 outsanding shares previously).

Therefore, Mithra publishes the updated following information :

  • Share capital: EUR 27,573,880.18
  • Total number of securities carrying voting rights: 37,664,245 (all ordinary shares)
  • Total number of voting rights (= denominator): 37,664,245 (all relating to ordinary shares)
  • Number of rights to subscribe securities carrying voting rights not yet issued:
    • Pursuant to the warrant plan of 2 March 2015: 635 warrants giving right to 1,047,750 shares
    • Pursuant to the warrant plan of 5 November 2018: 1,238,339 warrant giving right to 1,238,339 shares

Mithra Announces New Polymer Technology Development for a Leading Veterinarian Company

  • First veterinary R&D project concluded with one of the world’s largest animal health players, CEVA
  • Development of an innovative hormonal device for the bovine fertility market
  • Expansion of Mithra CDMO polymer technology expertise attracts new development partners

Liege, Belgium, 20 February 2019 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health announces today that it has signed a contract with the CEVA Animal Health group to develop a hormonal device for the veterinary market. CEVA Animal Health is one of the ten largest veterinary pharmaceutical groups in the world and develops products that meet the specific needs of the various sectors of this market, particularly bovines.

Mithra Strengthens Management Team With Key Appointments

  • Expansion of IR and Communications functions to support the execution of Mithra’s strategy

Liège, Belgium, 4 February 2019 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces it has strengthened its IR and Communications functions with the appointments of Ms. Alexandra Deschner as Investor Relations Officer and Ms. Maud Vanderthommen as Communications Manager.

 

Mithra announces 2019 financial calendar

Liege, Belgium, 22 January 2019 – 7:30  CET – Mithra (Euronext Brussels: MITRA), a company focused on women’s health, today announces its financial calendar for 2019 :

  • 1 March 2019 : Full Year Results 2018
  • 8 April 2019 : Annual Report 2018
  • 16 May 2019 : Annual General Shareholders Meeting
  • 19 September 2019 : Interim report 2019

This calendar and all corporate information on the Company, such as its financial statements, events or corporate presentations, is available on the Company’s website in the Investors’ section  (investors.mithra.com).

Mithra Wins BelMid Company of the Year 2018

Liège, Belgium, 18 January 2019 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, has been awarded BelMid Company of the Year 2018 by Euronext Brussels at its annual New Year’s Ceremony held in Brussels last night.

Mithra Announces Attendance at the 37th Annual J.P. Morgan Healthcare Conference

Liège, Belgium, 04 January 2019 – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, today announces that Chief Executive Officer Mr. François Fornieri and members of the executive management team will be attending the 37th Annual J.P. Morgan Healthcare Conference in San Francisco from the 7th to the 10th of January 2019.

For further information or to arrange a one-on-one meeting with Mithra’s management team in San Francisco, please contact:

Brandon Weiner – Westwicke Partners
Associate – Baltimore
+1-443-450-4190
Brandon.weiner@westwicke.com

 

Mithra Reduces Environmental Impact of CDMO facility in Belgium with the Installation of 1800 Solar Panels

Liège, Belgium, 21 November 2018 –  Mithra (Euronext Brussels: MITRA) announces that it has reduced the environmental impact of its CDMO facility in Belgium with the installation of 1800 solar panels. Mithra has also put in place an internal committee within its CDMO with the aim of reducing costs and minimizing the environmental impact of the company’s manufacturing activities.

2018 Update and 2019 Outlook Given at the CPHI Conference

  • Estelle® Oral Contraception programme on track – US/CANADA Phase III arm due to complete in Q4 2018; partnering discussions ongoing including for us market
  • Preparations for Phase III Donesta® trials moving ahead, including co-partnering discussions
  • Further Marketing authorisations obtained for MyRing™

Liège, Belgium, 10 October 2018 – 20:30 CEST – Mithra (Euronext Brussels: MITRA), a company dedicated to Women’s Health, provided an update on its key programmes at the CPHI world conference.